South Korea starts to distribute stocks of remdesivir, plans to purchase more in August

In a statement on June 30,  Korea Centers for Disease Control and Prevention (KCDC) said that it plans to resume talks for  purchase negotiations for breakthrough drug remdesivir in August 2020. Doses of drug were earlier donated to South Korea by US firm Gile Sciences Inc, however, country did t reveal count. Furr, KCDC stressed that limited doses would be preserved for critical patients of COVID-19, or severe pneumonia, and those with extremely low SP02 in need of supplement oxygen as nation started redistribution of doses.

While South Korea is first country to reveal drug purchase timeline, KCDC director Jeong Eun-kyeong said at a daily COVID-19 conference that  coronavirus patients with severe symptoms that developed in less than 10 days will be given drug. ditionally, patients with critical respiratory distress will also be ministered with remdesivir in early sts of disease. She ded, that  drug has been proven to be effective in moderating overall impact of coronavirus by a domestic panel of experts. Earlier this month, South Korea’s Ministry for Food and Drug Safety approved medicine's emergency use after it yielded positive results in COVID-19 patients in formal clinical trials.

In a statement, South Korea’s Ministry for Food and Drug Safety said that remdesivir could relieve symptoms of coronavirus and help improve patient’s condition faster. A study published in  New England Journal of Medicine h found that critical hospitalized COVID-19 patients who received Gile Sciences' antiviral drug showed “improved recovery time”. research was based on data from 538 patients who were ministered remdesivir in aptive Covid-19 Treatment Trial (ACTT), which was sponsored by  National Institute of Allergy and Infectious Diseases (NIAID) in US.   

Re: Coronavirus Live Updates: India's Total Tally At 5,85,493; 59.43% Patients Recovered

Re: Senate Extends Small Business Coronavirus Relief Program

Priced drug at $390 per vial

On June 29, Gile revealed that it has priced drug at $390 per vial in United States and or developed countries. Furr, company agreed to dispatch drug supply to United States over next three months.  pharma company, however, asked for some more weeks to make anti-viral drug available to COVID-19 patients in developing world, including in India, as per a report.

Furr, in a statement, company said that pharmaceutical firms that were seeking to manufacture drug domestically were all still working on furnishing safety and quality data. Although,  approval process for introduction of medicine was being fast-tracked. While  US pharma giant Gile Sciences was given  marketing authorization for drug, four companies, Hetero, Jubilant Life Sciences, Cipla, and Mylan NV were awaiting DCGI approval for manufacturing and selling drug in India.  

Re: Schalke Chairman Quits After Winless Run And Coronavirus Cases

Re: Coronavirus' Spre In GOP Territory, Explained In 6 Charts